Gene Biotherapeutics, Inc. (CRXM)
USD 0.0
(9900.0%)
USD 0.0
(9900.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | -100.0% |
| 2020 | 5.13 Million USD | 5.12% |
| 2019 | 4.88 Million USD | -15.64% |
| 2018 | 5.79 Million USD | 7.92% |
| 2017 | 5.36 Million USD | 21.94% |
| 2016 | 4.4 Million USD | 14.85% |
| 2015 | 3.83 Million USD | 57.81% |
| 2014 | 2.42 Million USD | 51.63% |
| 2013 | 1.6 Million USD | 10.96% |
| 2012 | 1.44 Million USD | 1.75% |
| 2011 | 1.41 Million USD | -31.94% |
| 2010 | 2.08 Million USD | -72.69% |
| 2009 | 7.63 Million USD | -30.96% |
| 2008 | 11.05 Million USD | 30.06% |
| 2007 | 8.49 Million USD | 186.68% |
| 2006 | 2.96 Million USD | 383.13% |
| 2005 | 613.5 Thousand USD | 919.45% |
| 2004 | 60.18 Thousand USD | -27.49% |
| 2003 | 82.99 Thousand USD | -15.99% |
| 2002 | 98.78 Thousand USD | -46.84% |
| 2001 | 185.84 Thousand USD | -31.38% |
| 2000 | 270.83 Thousand USD | -98.98% |
| 1999 | 26.57 Million USD | -43.08% |
| 1998 | 46.69 Million USD | 241.88% |
| 1997 | 13.65 Million USD | 49.68% |
| 1996 | 9.12 Million USD | 60.82% |
| 1995 | 5.67 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | -100.0% |
| 2020 FY | 5.13 Million USD | 5.12% |
| 2020 Q1 | 5.14 Million USD | 5.38% |
| 2020 Q2 | 5.01 Million USD | -2.51% |
| 2020 Q3 | 5.05 Million USD | 0.69% |
| 2020 Q4 | 5.13 Million USD | 1.62% |
| 2019 Q4 | 4.88 Million USD | 0.0% |
| 2019 FY | 4.88 Million USD | -15.64% |
| 2019 Q1 | - USD | 0.0% |
| 2018 FY | 5.79 Million USD | 7.92% |
| 2017 Q1 | 4.31 Million USD | -1.85% |
| 2017 FY | 5.36 Million USD | 21.94% |
| 2016 FY | 4.4 Million USD | 14.85% |
| 2016 Q1 | 4.07 Million USD | 6.41% |
| 2016 Q2 | 4.57 Million USD | 12.19% |
| 2016 Q3 | 4.29 Million USD | -6.14% |
| 2016 Q4 | 4.4 Million USD | 2.5% |
| 2015 Q3 | 3.4 Million USD | 12.01% |
| 2015 Q4 | 3.83 Million USD | 12.42% |
| 2015 Q2 | 3.04 Million USD | 11.7% |
| 2015 Q1 | 2.72 Million USD | 12.21% |
| 2015 FY | 3.83 Million USD | 57.81% |
| 2014 FY | 2.42 Million USD | 51.63% |
| 2014 Q1 | 2.25 Million USD | 41.03% |
| 2014 Q2 | 2.3 Million USD | 2.15% |
| 2014 Q3 | 2.31 Million USD | 0.54% |
| 2014 Q4 | 2.42 Million USD | 4.68% |
| 2013 Q1 | 1.25 Million USD | -13.26% |
| 2013 FY | 1.6 Million USD | 10.96% |
| 2013 Q4 | 1.6 Million USD | 35.85% |
| 2013 Q3 | 1.17 Million USD | -4.04% |
| 2013 Q2 | 1.22 Million USD | -1.87% |
| 2012 Q4 | 1.44 Million USD | 11.29% |
| 2012 Q3 | 1.29 Million USD | 13.3% |
| 2012 Q2 | 1.14 Million USD | -36.27% |
| 2012 Q1 | 1.79 Million USD | 26.61% |
| 2012 FY | 1.44 Million USD | 1.75% |
| 2011 Q1 | 1.9 Million USD | -8.68% |
| 2011 Q4 | 1.41 Million USD | -1.67% |
| 2011 Q3 | 1.44 Million USD | -20.26% |
| 2011 Q2 | 1.8 Million USD | -4.95% |
| 2011 FY | 1.41 Million USD | -31.94% |
| 2010 Q3 | 5.05 Million USD | 15.99% |
| 2010 FY | 2.08 Million USD | -72.69% |
| 2010 Q2 | 4.35 Million USD | -32.77% |
| 2010 Q1 | 6.47 Million USD | -15.11% |
| 2010 Q4 | 2.08 Million USD | -58.74% |
| 2009 Q1 | 28.81 Million USD | 160.77% |
| 2009 Q2 | 38.21 Million USD | 32.6% |
| 2009 Q3 | 24.47 Million USD | -35.96% |
| 2009 FY | 7.63 Million USD | -30.96% |
| 2009 Q4 | 7.63 Million USD | -68.82% |
| 2008 Q4 | 11.05 Million USD | 45.88% |
| 2008 Q1 | 8.39 Million USD | -1.21% |
| 2008 Q3 | 7.57 Million USD | -21.89% |
| 2008 FY | 11.05 Million USD | 30.06% |
| 2008 Q2 | 9.69 Million USD | 15.54% |
| 2007 Q1 | 1.91 Million USD | -35.37% |
| 2007 Q4 | 8.49 Million USD | 175.07% |
| 2007 Q2 | 3.27 Million USD | 70.92% |
| 2007 Q3 | 3.08 Million USD | -5.64% |
| 2007 FY | 8.49 Million USD | 186.68% |
| 2006 Q3 | 1.71 Million USD | 27.32% |
| 2006 Q4 | 2.96 Million USD | 72.95% |
| 2006 Q1 | 1.46 Million USD | 0.0% |
| 2006 Q2 | 1.34 Million USD | -7.99% |
| 2006 FY | 2.96 Million USD | 383.13% |
| 2005 Q3 | 95.57 Thousand USD | 30.27% |
| 2005 Q2 | 73.36 Thousand USD | 57.45% |
| 2005 FY | 613.5 Thousand USD | 919.45% |
| 2005 Q1 | 46.59 Thousand USD | -32.5% |
| 2004 Q4 | 69.03 Thousand USD | 14.71% |
| 2004 Q3 | 60.18 Thousand USD | -7.91% |
| 2004 Q2 | 65.34 Thousand USD | 34.26% |
| 2004 Q1 | 48.67 Thousand USD | -30.82% |
| 2004 FY | 60.18 Thousand USD | -27.49% |
| 2003 FY | 82.99 Thousand USD | -15.99% |
| 2003 Q4 | 70.35 Thousand USD | -15.22% |
| 2003 Q3 | 82.99 Thousand USD | -39.12% |
| 2003 Q2 | 136.32 Thousand USD | 191.8% |
| 2003 Q1 | 46.71 Thousand USD | -57.55% |
| 2002 Q4 | 110.05 Thousand USD | 11.41% |
| 2002 FY | 98.78 Thousand USD | -46.84% |
| 2002 Q2 | 648.71 Thousand USD | 13.49% |
| 2002 Q3 | 98.78 Thousand USD | -84.77% |
| 2002 Q1 | 571.6 Thousand USD | -0.25% |
| 2001 Q2 | 149.02 Thousand USD | 3.24% |
| 2001 Q3 | 185.84 Thousand USD | 24.7% |
| 2001 Q4 | 573.03 Thousand USD | 208.35% |
| 2001 FY | 185.84 Thousand USD | -31.38% |
| 2001 Q1 | 144.34 Thousand USD | -24.83% |
| 2000 Q1 | 1.14 Million USD | -95.8% |
| 2000 Q2 | 200.02 Thousand USD | -82.6% |
| 2000 Q4 | 192.01 Thousand USD | -29.1% |
| 2000 FY | 270.83 Thousand USD | -98.98% |
| 2000 Q3 | 270.83 Thousand USD | 35.4% |
| 1999 FY | 26.57 Million USD | -43.08% |
| 1999 Q4 | 27.37 Million USD | 0.0% |
| 1998 Q1 | 7 Million USD | 2.94% |
| 1998 Q2 | 1.5 Million USD | -78.57% |
| 1998 Q3 | 46.69 Million USD | 3012.82% |
| 1998 FY | 46.69 Million USD | 241.88% |
| 1997 FY | 13.65 Million USD | 49.68% |
| 1997 Q1 | 12.3 Million USD | 48.19% |
| 1997 Q2 | 7.6 Million USD | -38.21% |
| 1997 Q3 | 13.65 Million USD | 79.7% |
| 1997 Q4 | 6.8 Million USD | -50.21% |
| 1996 FY | 9.12 Million USD | 60.82% |
| 1996 Q4 | 8.3 Million USD | -9.03% |
| 1996 Q3 | 9.12 Million USD | 0.0% |
| 1995 FY | 5.67 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | 100.0% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 100.0% |
| Innovation1 Biotech Inc. | 3.5 Million USD | 100.0% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | 100.0% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | 100.0% |